| ²é¿´: 402 | »Ø¸´: 2 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
[½»Á÷]
Çó·Òë³ÉÖÐÎÄ
|
|||
|
To date, different mutations have been reported that result in a complete deficiency, including: two deletions (295¨C298delTCAT and 1897delC), one splice-site mutation (IVS14+IG>A), four missense mutations (85T>C, 703C>T, 2657G>A, and 2983 G>T), a deletion of two nucleotides (1039¨C1040delTG), and the point mutations P86L, S201R, S492L, D949V and H978R [13]. The 85T>C mutation might be a common polymorphism, although functional analysis of a recombinantly expressed human protein carrying the 85T>C mutation showed no significant residual mutant enzyme activity [10,14]. An in-depth discussion of the clinical import of DPD can be found in a number of review articles, and two examples are provided in Refs. [37,38], which discuss the role of DPD in cancer therapy with 5FU |
» ²ÂÄãϲ»¶
¿¼Ñе÷¼Á
ÒѾÓÐ3È˻ظ´
»¯¹¤Ñ§Ë¶294·Ö£¬Çóµ¼Ê¦ÊÕÁô
ÒѾÓÐ25È˻ظ´
327Çóµ÷¼Á
ÒѾÓÐ12È˻ظ´
085600²ÄÁÏÓ뻯¹¤329·ÖÇóµ÷¼Á
ÒѾÓÐ11È˻ظ´
Ò»Ö¾Ô¸»¦9£¬326ÇóÉúÎïѧµ÷¼Á
ÒѾÓÐ8È˻ظ´
ÉúÎïѧ308·ÖÇóµ÷¼Á£¨Ò»Ö¾Ô¸»ª¶«Ê¦´ó£©½ÓÊÜ¿çרҵ
ÒѾÓÐ3È˻ظ´
±¾¿ÆÖ£ÖÝ´óѧ£¬Ò»Ö¾Ô¸»ª¶«Ê¦·¶´óѧ282Çóµ÷¼Á
ÒѾÓÐ33È˻ظ´
291 Çóµ÷¼Á
ÒѾÓÐ31È˻ظ´
0854µ÷¼Á
ÒѾÓÐ13È˻ظ´
¿¼ÑÐÇóµ÷¼Á
ÒѾÓÐ10È˻ظ´
» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:
˫һÁ÷ÄϾ©Ò½¿Æ´óѧÕмÆËã»ú¡¢ÉúÎïÐÅÏ¢µÈ·½ÏòÑо¿Éúµ÷¼Á
+1/140
ÎïÀíѧµ÷¼Á
+1/91
̫ԿƼ¼´óѧ˶ʿ
+1/85
Î÷°²½»Í¨´óѧÉÂÎ÷Ê¡¿Æ¼¼´´ÐÂÍŶӳ£ÄêÕÐÆ¸±£ËÍÉúºÍ¿¼ÑÐÉú£¬Ã¿Äê2-4¸öÃû¶î
+1/40
ɽÎ÷´óѧ¹âÁ¿×Ó¼¼ÊõÓëÆ÷¼þ¹ú¼ÒʵÑéÊÒÕÐÊÕÎïÀí¡¢¹âѧ¡¢²ÄÁÏרҵ2026¼¶²©Ê¿¡¢Ë¶Ê¿Ñо¿Éú
+1/38
Ê¡ÖØµãʵÑéÊÒÕÐÊÕµ÷¼ÁÉú£¨Ò»Ö¾Ô¸07¿ªÍ·×¨Òµ£©£¬º£ÑóÉúÎïרҵÃû¶î³ä×ã
+1/15
ËÙ±¨Ãû£¡£¡£¡²ÄÁÏ¡¢»¯Ñ§µÈÏà¹Ø×¨Òµ¾ù¿Éµ÷¼Á
+1/10
¿óÒµ¹¤³ÌѧÊõÑо¿ÉúÓв¿·Öµ÷¼ÁÃû¶î
+1/10
²ÄÁÏÓ뻯¹¤×¨Òµ»¹ÓдóÁ¿Ö¸±ê£¬»¶Ó´ó¼Òµ÷¼Á£¬µ÷¼ÁϵͳÒѾ¿ª·Å
+1/10
±±¾©»¯¹¤´óѧ²ÄÁÏѧԺ¸ß·Ö×Ó΢ÕëʵÑéÊÒÕÐÊÕµ÷¼Á
+1/9
ºÓÄÏʦ´óÈ«¹úÖØµãʵÑéÊÒ¡ª0780ҩѧ¡¢08600ÉúÎïÓëÒ½Ò©ÈÔÓе÷¼ÁÖ¸±ê£¡
+1/9
ÕÔËÉ·½½ÌÊÚÁªºÏɽ´óÓÚΰӾ½ÜÇà¡¢ÑÓÊÀ´óJong-Hyun AhnԺʿÕв©Ê¿ºó ¡¢²©Ê¿Ñо¿Éú
+1/9
ÆëÆë¹þ¶û´óѧÀîÀò¿ÎÌâ×é³ÏÕÐ2026¼¶¿¼Ñе÷¼ÁÉú£¨Ñ§Ë¶ºÍר˶£©
+1/6
¹þ¶û±õÒ½¿Æ´óѧÀîÀÏʦ¿ÎÌâ×éÕÐÊÕÉúÎïÐÅϢѧ·½Ïò²©Ê¿¡¢Ë¶Ê¿Ñо¿Éú
+1/4
ÆëÆë¹þ¶û´óѧÀîÀò¿ÎÌâ×é³ÏÕÐ2026¼¶¿¼Ñе÷¼ÁÉú£¨Ñ§Ë¶ºÍר˶£©
+1/4
27Ä격ʿ×Ô¼ö
+1/4
ÕÐÊÕ0703ºÍ08¿ªÍ·µÄѧ˶ר˶¾ù¿É£¬ÏßÉϸ´ÊÔ
+2/4
Ò»Ö¾Ô¸211µç×ÓÐÅÏ¢347Çóµ÷¼Á
+1/2
ÖйúÃñº½´óѧÕÐÊÕ2026ÄêÎïÀíѧѧÊõ˶ʿ
+1/2
ÖØÇìÈýÏ¿¿Æ¼¼´óѧ¹âÏË´«¸Ð¿ÎÌâ×éÕе÷¼Á˶ʿÑо¿Éú£¨4ÔÂ13ÈÕµç´Å³¡Óë΢²¨¼¼Êõרҵ£©
+1/1
µØÍ¼ÎÏÅ£
Òø³æ (СÓÐÃûÆø)
- ·ÒëEPI: 9
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 339.4
- Ìû×Ó: 71
- ÔÚÏß: 16.5Сʱ
- ³æºÅ: 804596
ЦÊÀ¿ñÁú(½ð±Ò+25, ·ÒëEPI+1): ллÄã 2011-03-11 20:27:42
|
ÄúÊDz»ÊǰÑһƪDPDµÄ×ÛÊöÒ»µãµãÌùѽ¡£ ĿǰÒѱ¨µÀÓжà¸öÍ»±äµ¼ÖÂÍêÈ«¹¦ÄÜȱʧ£¬ÕâЩͻ±äÓУºÁ½¸öȱʧͻ±ä£¨295¨C298delTCAT and 1897delC£©£¬Ò»¸ö¼ô½ÓλµãÍ»±ä(IVS14+IG>A)£¬4¸ö´íÒåÍ»±ä(85T>C, 703C>T, 2657G>A, and 2983 G>T)£¬Ò»¸öÁ½¸öºËÜÕËáµÄȱʧͻ±ä(1039¨C1040delTG)ºÍ¼¸¸öµãÍ»±äP86L, S201R, S492L, D949V and H978R¡£85T>CÍ»±ä¿ÉÄÜÊÇÒ»¸ö±È½ÏÆÕ±éµÄ¶à̬ÐÔ£¬µ«Ð¯´ø85T>CÍ»±äµÄÖØ×éÈËDPDµ°°×²¢Ã»ÓÐÃ÷ÏÔµÄÍ»±äøµÄ»îÐÔ²ÐÓà¡£´óÁ¿×ÛÊöÒѾÉîÈëÌÖÂÛÁËDPDµÄÖØÒªÁÙ´²×÷Óã¬ÎÄÏ×37£¬38ÖоÍÓÐÁ½¸öÀý×Ó£¬ÕâÁ½Æª×ÛÊöÌÖÂÛÁËDPDÔÚ5FUÖÎÁư©Ö¢ÖеÄ×÷Óᣠ|
2Â¥2011-03-11 10:50:33
3Â¥2011-03-11 20:40:20














»Ø¸´´ËÂ¥